When they targeted FGFR2 along with EGFR-a protein known to be overactive in pancreatic cancer-they saw even better results. Fewer "early versions of cancer" formed in the first place.

When they targeted FGFR2 along with EGFR -- a protein known to be overactive in pancreatic cancer -- they saw even better results. Fewer "early versions of cancer" formed in the first place.

She and her colleagues recently discovered that KRAS gets mutated from another gene called FGFR2, making “those ‘early versions’ of pancreatic cancer become much more aggressive.” The gene ...

More information: FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development, Cancer Research (2025). DOI: 10.1158/0008-5472.CAN-24-4576 ...

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation ...

Notably, FGFR2 expression in murine precancerous lesions correlated with an increase in mutant KRAS signaling. "We know that precancerous pancreatic lesions often carry KRAS mutations," said Tonelli.

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers—including intrahepatic cholangiocarcinoma, endometrial, breast, gastric, and bladder cancers. However ...